There are errors in the “Hemoglobin (mmol/L)” values in Table 1, Table 2 and Table 3. Please see the corrected tables here.
Table 1. Main Baseline characteristics according to dialysis modality.
| PDa patients | HDb patients | p | |
|---|---|---|---|
| (n = 237) | (n = 237) | ||
| Males (%) | 137 (58) | 146 (61.8) | 0.45 |
| Age (years) | 52 [42;63] | 55 [43;63] | 0.11 |
| Smoker (former/current) (%) | 135 (57) | 137 (58) | 0.92 |
| Diabetes (%) | 43 (18.1) | 43 (18.1) | 1 |
| Hypertension (%) | 219 (92.4) | 199 (84) | 0.007 |
| Dyslipidemia (%) | 153 (64.6) | 123 (47.7) | <0.001 |
| Etiology of renal disease (%): | 0.670 | ||
| Diabetic nephropathy | 25 (10.5) | 27 (11.4) | |
| Vascular disease | 23 (9.7) | 29 (12.2) | |
| Others | 189 (79.7) | 181 (76.4) | |
| Dialysis time (months) | 13.7 [6.2;28.9] | 14.3 [6.41;28.6] | 0.91 |
| Body mass index (kg/m2) | 26.4 [23.3;29.2] | 25.3 [23;28.6] | 0.23 |
| Systolic Blood Pressure (mmHg) | 140 [129;159] | 135 [120;151] | 0.001 |
| Diastolic Blood Pressure (mm Hg) | 83 [77;94] | 80 [70;88] | <0.001 |
| Pulse Pressure (mmHg) | 56 [45;69] | 55 [46;63] | 0.53 |
| Serum glucose (mmol/L) | 5.05 [2.96;6.10] | 5.05 [4.56;6.10] | 0.838 |
| Urea (mmol/L) | 21.5 [17.6;25.8] | 20.8 [15.8;25] | 0.07 |
| Creatinine (μmol/L) | 682.5 [519.8;884] | 727.5 [574.6;884] | 0.1 |
| Total colesterol (mmol/L) | 4.58 [3.99;5.20] | 3.91 [3.37;4.53] | <0.001 |
| HDL-cholesterol (mmol/L) | 1.22 [1.01;1.48] | 1.09 [0.90;1.29] | <0.001 |
| LDL-cholesterol (mmol/L) | 2.66 [2.07;5.15] | 2.07 [1.63;2.64] | <0.001 |
| Triglycerides (mmol/L) | 1.34 [1.07;1.87] | 1.41 [1.03;1.92] | 0.75 |
| Serum uric acid (μmol/L) | 345.1 [303.4;401.6] | 362.9 [321.3;425.4] | 0.006 |
| hs C-Reactive Protein (nmol/L) | 19 [8.95;49.9] | 22.47 [10.09;58.66] | 0.23 |
| Albumin (mol/L) | 0.59 [0.54;0.62] | 0.59 [0.54;0.64] | 0.025 |
| Hemoglobin (mmol/L) | 7.2 [7.01;8.01] | 7.26 [6.70;7.76] | <0.001 |
| Corrected calcium (mmol/L) | 2.3 [2.20;2.42] | 2.26 [2.16;2.36] | <0.001 |
| Phosphate (mmol/L) | 1.6 [1.35;1.84] | 1.54 [1.25;1.79] | 0.035 |
| iPTH (pmolL) | 22.7 [14.9;35.4] | 25.7 [14.3;36.4] | 0.23 |
| 25-hydroxy-vitamin D (nmol/L) | 28.9 [20.9;41.2] | 37.4 [26.4;48.7] | <0.001 |
| 1-25-hydroxy-vitamin D (pmol/L) | 13.6 [9.72;19.9] | 13.8 [9.31;22.3] | 0.54 |
| Treatments | |||
| Antihypertensive (%): | 214 (90.3) | 159 (67.1) | <0.001 |
| ACEIc (%) | 66 (27.8) | 41 (17.3) | 0.008 |
| ARBsd (%) | 111 (46.8) | 54 (22.8) | <0.001 |
| Diuretics (%) | 128 (54) | 45 (19) | <0.001 |
| Statins (%) | 137 (57.8) | 110 (46.4) | 0.017 |
| Phosphate binders (%): | 198 (83.5) | 189 (79.7) | 0.343 |
| Binders without Cae (%) | 126 (53.2) | 138(58.2) | 0.309 |
| Binders with Cae (%) | 42 (47.2) | 40 (47.1) | 1 |
| Cae intake (binders) (gr/day) | 1.5 [1;2] | 1.65 [1;3] | 0.027 |
| Calcitriol/Paricalcitol (%) | 97 (40.9) | 122 (51.5) | 0.027 |
| Calcifedol /%) | |||
| Cholecalciferol (%) | 27 (11.4) | 8 (3.38) | 0.002 |
| Cinacalcet (%) | 11(4.64) | 8 (3.38) | 0.640 |
| Antiplatelet drugs (%): | 27 (24.1) | 68 (28.7) | 0.297 |
| ESAf(%) | 181(76.4) | 198 (83.5) | 0.066 |
| Renal transplantation centre (%) | 88 (37.1) | 62 (26.2) | 0.014 |
| Plaque presence (%) | 123 (51.9) | 143 (60.3) | 0.08 |
| Number of territories with plaque | 2 [1.0;3.0] | 2 [1.0;3.0] | 0.285 |
| cIMTg (mm) | 0.65 [0.56;0.79] | 0.70 [0.6;0.84] | 0.009 |
| Ankle-Brachial index (%) | |||
| ABI < 0.9 | 37 (15.7) | 23 (9.91) | 0.08 |
| ABI >0.9-<1.4 | 175 (74.5) | 144 (62.1) | 0.005 |
| ABI > 1.4 | 23 (9.79) | 65 (28) | <0.001 |
Data are presented as median [interquartile range], mean (standard deviation) or n(%).
a Peritoneal dialysis
b Hemodialysis
c Angiotensin converting enzyme inhibitors
d Angiotensin II receptor blockers
e Calcium
f Erythropoiesis stmulating agents
g Common carotid artery intima media thickness
Table 2. Main Baseline characteristics of patients with 2-years follow-up according to dialysis modality.
| PDa patients | HDb patients | p | |
|---|---|---|---|
| (n = 82) | (n = 85) | ||
| Males (%) | 47 (57.3) | 48 (52.2) | 0.6 |
| Age (years) | 53 [42.5;63] | 55 [44.8;64] | 0.39 |
| Smoker (former/current) (%) | 49 (59.8) | 48 (52.2) | 0.9 |
| Diabetes (%) | 14 (17.1) | 14 (15.2) | 0.9 |
| Hypertension (%) | 75 (91.5) | 79 (86) | 0.359 |
| Dyslipidemia (%) | 58 (70.7) | 55 (59.8) | 0.176 |
| Etiology of renal disease (%): | 0.670 | ||
| Diabetic nephropathy | 7 (8.54) | 8 (8.7) | |
| Vascular disease | 8 (9.76) | 13 (14.1) | |
| Others | 67 (81.7) | 71 (77.2) | |
| Dialysis time (months) | 10.5 [4.46;19.2] | 11.5 [5.82;25.8] | 0.131 |
| Body mass index (kg/m2) | 26.4 [23.3;28.4] | 26.1 [23;4.32.2] | 0.446 |
| Systolic Blood Pressure (mmHg) | 145 (24.4) | 138 (21.8) | 0.03 |
| Diastolic Blood Pressure (mm Hg) | 87.5 (12.2) | 78.8 (13.3) | <0.001 |
| Pulse Pressure (mmHg) | 56 [44;69] | 56.5 [47;70.2] | 0.579 |
| Serum glucose (mmol/L) | 5.16 [4.72;5.61] | 5.23 [4.55;6.05] | 0.931 |
| Urea (mmol/L) | 22.11 (6.76) | 20.31 (6.13) | 0.053 |
| Creatinine (μmol/L) | 596.7 [468.5;792.1] | 676.3 [583.4;837.2] | 0.815 |
| Total colesterol (mmol/L) | 4.75 [4.2;5.43] | 3.9 [3.2;4.45] | 0.258 |
| HDL-cholesterol (mmol/L) | 1.21 [1;1.52] | 1.1 [0.88;1.21] | 0.005 |
| LDL-cholesterol (mmol/L) | 3.46 [2.28;3.05] | 3.36 [2.56;4.4] | <0.001 |
| Triglycerides (mmol/L) | 1.53 [1.09;2.02] | 1.48 [1.13;1.94] | 0.940 |
| Serum uric acid (μmol/L) | 350.4 (72.6) | 369.4 (70.78) | 0.093 |
| hs C-Reactive Protein (nmol/L) | 26.28 [10;61.24] | 24 [10.47;62.48] | 0.815 |
| Albumin (mol/L) | 0.59 [0.53;0.62] | 0.59 [0.54;0.64] | 0.471 |
| Hemoglobin (mmol/L) | 7.24 (0.80) | 6.82 (0.84) | 0.002 |
| Corrected calcium (mmol/L) | 2.32 [2.22;2.4] | 2.25 [2.16;2.32] | 0.031 |
| Phosphate (mmol/L) | 1.52[1.32;1.81] | 1.55 [1.29;1.81] | 0.965 |
| iPTH (pmolL) | 21.1 [15.48;34.25] | 26.51 [16.2;41] | 0.182 |
| 25-hydroxy-vitamin D (nmol/L) | 30.5 [21.75;43.75] | 35.5 [27;48] | 0.014 |
| 1-25-hydroxy-vitamin D (pmol/L) | 15.45 [10.3;22.7] | 14.4 [10.15;25.75] | 0.862 |
| Treatments | |||
| Antihypertensive (%): | 72 (87.8) | 60 (65.2) | 0.001 |
| ACEIc (%) | 20 (24.4) | 15 (16.3) | 0.255 |
| ARBsd (%) | 37 (45.1) | 25 (27.2) | 0.021 |
| Diuretics (%) | 27 (32.6) | 28 (32.9) | 0.837 |
| Statins (%) | 48 (58.3) | 50 (54.3) | 0.687 |
| Phosphate binders (%): | 66 (80.5) | 68 (73.9) | 0.396 |
| Binders without Cae (%) | 38 (46.3) | 48(52.2) | 0.538 |
| Binders with Cae (%) | 42 (47.2) | 40 (47.1) | 1 |
| Cae intake (binders) (gr/day) | 1 [1;1.5] | 1.5 [1;2.5] | 0.03 |
| Calcitriol/Paricalcitol (%) | 34 (41.5) | 44 (47.8) | 0.490 |
| Calcifedol /%) | 8 (9.76) | 5 (5.43) | 0.428 |
| Cholecalciferol (%) | 2 (2.44) | 4 (4.35) | 0.685 |
| Cinacalcet (%) | 18 (22) | 24 (26.1) | 0.646 |
| Antiplatelet drugs (%): | 22 (26.8) | 27 (29.3) | 0.842 |
| ESAf (%) | 62 (75.6) | 77 (83.7) | 0.255 |
| Renal transplantation centre (%) | 27 (32.9) | 20 (21.7) | 0.137 |
| Plaque presence (%) | 44 (53.7) | 53 (57.6) | 0.711 |
| Number of territories with plaque | 2 [1.0;2.0] | 2 [1.0;3.0] | 0.149 |
| cIMTg (mm) | 0.65 [0.57;0.75] | 0.72 [0.62;0.86] | 0.005 |
| Ankle-Brachial index (%) | <0.001 | ||
| ABI <0.9 | 10 (12.2) | 7 (7.78) | |
| ABI >0.9-<1.4 | 66 (80.5) | 55 (61.1) | |
| ABI > 1.4 | 6 (7.32) | 21 (31.1) |
Data are presented as median [interquartile range], mean (standard deviation) or n (%).
a Peritoneal dialysis
b Hemodialysis
c Angiotensin converting enzyme inhibitors
d Angiotensin II receptor blockers
e Calcium
f Erythropoiesis stimulating agents
g Common carotid artery intima media thickness
Table 3. Main Baseline characteristics of patients with 2-years follow-up according to dialysis modality.
| AVDa progression | Non AVD progression | p | |
|---|---|---|---|
| (n = 89) | (n = 85) | ||
| Males (%) | 50 (56.2) | 45 (52.9) | 0.78 |
| Age (years) | 57 [48;65] | 50 [39;62] | 0.004 |
| Smoker (former/current) (%) | 53 (59.6) | 44 (51.8) | 0.38 |
| Diabetes (%) | 20 (22.5) | 8 (9.41) | 0.033 |
| Hypertension (%) | 79 (88.8) | 75 (88.2) | 1 |
| Dyslipidemia (%) | 59 (66.3) | 54 (63.5) | 0.824 |
| Etiology of renal disease (%): | 0.165 | ||
| Diabetic nephropathy | 25 (10.5) | 27 (11.4) | |
| Vascular disease | 23 (9.7) | 29 (12.2) | |
| Others | 69 (77.5) | 69 (81.2) | |
| Dialysis time (months) | 10.2 [4.4;23.2] | 11.8 [6.47;22.5] | 0.27 |
| Body mass index (kg/m2) | 27 [23.6;30.7] | 26.1 [23.1;28.8] | 0.156 |
| Systolic Blood Pressure (mmHg) | 142 (24.3) | 141 (24.3) | 0.735 |
| Diastolic Blood Pressure (mm Hg) | 82 (13.5) | 83.9 (13.5) | 0.343 |
| Pulse Pressure (mmHg) | 60 [44;74] | 56 [45;66] | 0.326 |
| Serum glucose (mmol/L) | 5.18 [4.54;6.10] | 5.05 [4.49;5.66] | 0.157 |
| Urea (mmol/L) | 18.3 (5.25) | 18.3 (5.21) | 0.984 |
| Creatinine (μmol/L) | 610 [486.2;797.4] | 662.1 [557.8;839.8] | 0.089 |
| Total colesterol (mmol/L) | 4.14 [3.63;4.89] | 4.45 [3.57;5.33] | 0.258 |
| HDL-cholesterol (mmol/L) | 1.10 [0.93;1.39] | 1.16 [0.96;1.37] | 0.561 |
| LDL-cholesterol (mmol/L) | 2.30 [1.85;2.82] | 2.61 [1.81;2.98] | 0.264 |
| Triglycerides (mmol/L) | 1.51 [1.11;2.10] | 1.38 [1.07;1.92] | 0.528 |
| Serum uric acid (μmol/L) | 370.5 (72.6) | 350.4 (70.8) | 0.084 |
| hs C-Reactive Protein (nmol/L) | 37.7 [13.8;65.9] | 18.5 [8.4;54.2] | 0.04 |
| Albumin (mol/L) | 0.59 [0.0.53;0.63] | 0.59 [0.54;0.62] | 0.613 |
| Hemoglobin (mmol/L) | 7 (0.95) | 7 (0.80) | 0.962 |
| Corrected calcium (mmol/L) | 2.31 [2.19;2.4] | 2.26 [2.12;2.37] | 0.419 |
| Phosphate (mmol/L) | 1.52 [1.26;1.81] | 1.55 [1.36;1.84] | 0.292 |
| iPTH (pmolL) | 24.7 [15.9;38.1] | 23.3 [15.27;36.7] | 0.586 |
| 25-hydroxy-vitamin D (nmol/L) | 30.9 [22.8;42.9] | 36.4 [26.7;48.7] | 0.043 |
| 1-25-hydroxy-vitamin D (pmol/L) | 14.9 [10.0;24.5] | 13.6 [9.7;22.3] | 0.602 |
| Treatments | |||
| Antihypertensive (%): | 68 (76.4) | 64 (75.3) | 1 |
| ACEIb (%) | 18 (20.2) | 17 (20) | 1 |
| ARBsc (%) | 29 (32.6) | 33 (38.8) | 0.483 |
| Diuretics (%) | 27 (32.6) | 28 (32.9) | 0.837 |
| Statins (%) | 51 (57.3) | 47 (55.3) | 0.9 |
| Phosphate binders (%): | 68 (76.4) | 66 (77.6) | 0.98 |
| Binders without Cad (%) | 39 (43.8) | 47 (55.3) | 0.173 |
| Binders with Cad (%) | 42 (47.2) | 40 (47.1) | 1 |
| Cad intake (binders) (gr/day) | 1 [1;1.5] | 1.5 [1;2.5] | |
| Calcitriol/Paricalcitol (%) | 45 (50.6) | 33 (38.8) | 0.16 |
| Calcifedol /%) | 9 (10.1) | 4 (4.71) | 0.286 |
| Cholecalciferol (%) | 3 (3.37) | 3 (3.53) | 1 |
| Cinacalcet (%) | 19 (21.3) | 23 (27.1) | 0.482 |
| Antiplatelet drugs (%): | 27 (30.3) | 22 (25.9) | 0.628 |
| ESAe (%) | 66 (74.2) | 73 (85.9) | 0.082 |
| Renal transplantation centre (%) | 22 (24.7) | 25 (29.4) | 0.599 |
| Plaque at baseline (%) | 64 (71.9) | 33 (33.8) | <0.001 |
| Number of territories with plaque | 2 [1.0;3.0] | 2 [1.0;3.0] | 0.398 |
| cIMTf (mm) | 0.73 [0.65;0.89] | 0.64 [0.56;0.74] | <0.001 |
| Ankle-Brachial index (%) | |||
| ABI <0.9 | 11 (12.5) | 6 (7.14) | 0.357 |
| ABI >0.9-<1.4 | 57 (64.8) | 64 (76.2) | 0.141 |
| ABI > 1.4 | 20 (22.7) | 14 (16.7) | 0.420 |
| Dialysis modality: | 0.437 | ||
| Hemodialysis | 44 (49.4) | 48 (56.5) | |
| Peritoneal dialysis | 45 (50.6) | 37 (43.5) |
Data are presented as median [interquartile range], mean (standard deviation) or n (%).
a Atheromatous vascular disease
b Angiotensin converting enzyme inhibitors
c Angiotensin II receptor blockers
d Calcium
e Erythropoiesis stimulating agents
f Common carotid artery intima media thickness
Reference
- 1.Borràs Sans M, Pérez-Fontán M, Martinez-Alonso M, Bajo A, Betriu À, Valdivielso JM, et al. (2017) The modality of dialysis does not influence atheromatous vascular disease progression or cardiovascular outcomes in dialysis patients without previous cardiovascular disease. PLoS ONE 12(11): e0186921 https://doi.org/10.1371/journal.pone.0186921 [DOI] [PMC free article] [PubMed] [Google Scholar]